Juliette Fremaux

This inventor holds 5 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Ureka Sarl, Centre National De La Recherche Scientifique. Active years: 2019-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Juliette Fremaux. Retrieved from https://idiyas.com/inventor/juliette-fremaux

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 3)

% Patents Active = 80.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 6)

Average Co-Inventor Count = 4.7

ph-index = 2

Forward Citations = 8(Granted Patents)

Company Filing History:

Centre National De La Recherche Scientifique

patents

where one patent can have more than one assignee

Years Active: 2019-2022

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11285219 - Peptide-oligourea hybrid compounds (2022-03-29),

2. 11267861 - Peptide-oligourea foldamer compounds and methods of their use (2022-03-08),

3. 10889627 - Pro-drug peptide with improved pharmaceutical properties (2021-01-12),

4. 10398750 - Peptide-oligourea chimeric compounds and methods of their use (2019-09-03),

5. 10233213 - Foldamer helix bundle-based molecular encapsulation (2019-03-19),

Title: The Innovative Contributions of Juliette Fremaux

Introduction

Juliette Fremaux is a prominent inventor based in Pessac, France. She has made significant contributions to the field of peptide-oligourea hybrid compounds, holding a total of five patents. Her work focuses on the synthesis and application of novel therapeutic compounds.

Latest Patents

Fremaux's latest patents include innovative peptidomimetic foldamers. The first patent describes peptide-amino urea hybrid peptidomimetic foldamers, which consist of an alpha amino acid peptide portion and an oligourea portion. The second patent outlines compositions and methods for producing therapeutic compounds, emphasizing the administration of oligomeric compounds for the treatment and prevention of diseases in mammals. These compounds may be combined with pharmaceutically acceptable excipients or additional pharmacologically active agents.

Career Highlights

Throughout her career, Juliette Fremaux has worked with notable organizations such as Ureka Sarl and the Centre National de la Recherche Scientifique. Her experience in these institutions has allowed her to advance her research and contribute to the scientific community.

Collaborations

Fremaux has collaborated with esteemed colleagues, including Gilles Guichard and Robert H. Zimmer. These partnerships have further enriched her research and innovation in the field.

Conclusion

Juliette Fremaux's work in peptide-oligourea hybrid compounds showcases her dedication to advancing therapeutic solutions. Her patents reflect her innovative spirit and commitment to improving health outcomes through scientific research.

Profile summary based on public USPTO records.